Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BAE, QinetiQ could benefit from $95bn US aid package, says JPMorgan

(Sharecast News) - UK-listed defence peers BAE Systems and QinetiQ could both benefit from the recent passing of a $95.3bn US aid package to Ukraine, Israel and Indo-Pacific partners. On Saturday, the US House of Representatives approved around $67bn in extra spending for military equipment and roughly $29bn for humanitarian aid and other items. The package, which is supported by both the Senate and the president, should be disbursed quickly, JPMorgan said.

"To put this in context, our US A&D analyst Seth Seifman forecasts that the US defence investment budget in fiscal 2024 would be $319bn before this supplemental budget; thus the uplift in spending is very significant," said JPMorgan analyst David Perry.

"We also believe that the supplemental budget shows that the fears by some investors over the future direction of US defence spending may be overdone."

The companies in JPMorgan's European defence coverage with the modest direct exposure to supplementary defence budget are BAE Systems, where 43% of 2023 sales came from the US, QineitiQ (26%), along with Italian aerospace group Leonardo (20%) and German engineer RENK (20%).

BAE and QinetiQ were up both trading more than 1% higher on Monday morning in London - though in line with the wider market.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.